Orchestra BioMed
OBIO
77 hedge funds and large institutions have $119M invested in Orchestra BioMed in 2026 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 22 increasing their positions, 15 reducing their positions, and 13 closing their positions.
92% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 13
47% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 15
22% more capital invested
Capital invested by funds: $98.2M → $119M (+$21.2M)
18% more funds holding
Funds holding: 65 → 77 (+12)
6.78% more ownership
Funds ownership: 39.46% → 46.25% (+6.8%)
58% less call options, than puts
Call options by funds: $56K | Put options by funds: $132K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$7.67M |
| 2 |
RI
RTW Investments
New York
|
+$5.11M |
| 3 |
UBS AM
Chicago,
Illinois
|
+$2.63M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.14M |
| 5 |
RHJA
Rice Hall James & Associates
San Diego,
California
|
+$1.66M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$2.99M |
| 2 |
AAA
Affinity Asset Advisors
New York
|
-$1.51M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$801K |
| 4 |
6CM
683 Capital Management
New York
|
-$786K |
| 5 |
Vanguard Capital Management
Malvern,
Pennsylvania
|
-$742K |
OBIO Hedge Fund Activity: Q2 2026 in Review
77 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in Orchestra BioMed (OBIO) for Q2 2026, worth a combined $119M — up 22% from $98.2M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new OBIO positions and 13 closed out — a net gain of 12 holders — while 22 added to existing stakes and 15 trimmed.
The largest buyer was BlackRock, adding an estimated $7.67M. The largest seller was Millennium Management, exiting entirely with an estimated $2.99M sold.
- 77 institutional investors held Orchestra BioMed (OBIO) as of Q2 2026, up from 65 in Q1 2026.
- Funds reported $119M of Orchestra BioMed stock for Q2 2026, up 22% quarter-over-quarter.
- 25 funds opened new Orchestra BioMed positions in Q2 2026 and 13 closed out, a net change of +12 holders.
- The largest Orchestra BioMed buyer in Q2 2026 was BlackRock, an estimated $7.67M added.
- The largest Orchestra BioMed seller in Q2 2026 was Millennium Management, an estimated $2.99M sold.
Based on aggregated 13F filings for Q2 2026.